The results of this study demonstrate that chronic empagliflozin treatment promotes nephroprotection in CsA nephropathy, by reducing the increase in blood pressure caused by CsA administration and by preventing renal fibrosis, inflammatory cell infiltration and tyrosine hydroxylase expression, used as marker of sympathetic nerve activity. The gene discussed is TH; the disease is renal fibrosis.